SUO 2021 - 22nd Annual Meeting of the Society of Urologic Oncology
Dec 01 - Dec 03, 2021 | OrlandoFLUS
LARVOL is not affiliated with 22nd Annual Meeting of the Society of Urologic Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 19 abstracts linked to Trials
THE EFFICACY OF ENZALUTAMIDE (ENZA) PLUS ANDROGEN DEPRIVATION THERAPY (ADT) ON OLIGOMETASTATIC HORMONE-SENSITIVE PROSTATE CANCER: EXTENDED POST HOC ANALYSIS OF ARCHES
DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE PHASE 3 CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS WHO UNDERWENT SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA
SAFETY, TOLERABILITY, AND EFFICACY OF TAR-200 IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO WERE UNFIT FOR CURATIVE INTENT THERAPY: A PHASE 1 TRIAL
ANTI-ADENOVIRUS ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE DURABILITY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: RESULTS FROM A PHASE 3 CLINICAL TRIAL
PATIENT-REPORTED SEXUAL AND URINARY FUNCTION IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER FOLLOWING APALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY IN SPARTAN AND TITAN
SAFTEY AND EFFICACY OF FIRST-IN-HUMAN PHASE I STUDY OF INTRAVESCIAL PEMBROLIZUMAB AND BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
CHANGES IN THE URINE IMMUNE MICROENVIRONMENT IN RESPONSE TO INTRAVESICAL PEMBROLIZUMAB AND BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
DIAGNOSTIC PERFORMANCE OF PIFLUFOLASTAT F 18-PET/CT IN MEN WITH BIOCHEMICAL RECURRENCE OF PROSTATE CANCER AFTER DEFINITIVE TREATMENT: A CONDOR STUDY SUBANALYSIS
PHASE 3 VERACITY CLINICAL STUDY OF SABIZABULIN IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED ON AN ANDROGEN RECEPTOR TARGETING AGENT
SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF A NEOADJUVANT GEMCITABINE INTRAVESICAL DRUG DELIVERY SYSTEM (TAR-200) IN MUSCLE-INVASIVE BLADDER CANCER PATIENTS: A PHASE 1 TRIAL
THE OBESITY PARADOX IN PATIENTS WITH MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER RECEIVING NEOADJUVANT IMMUNOTHERAPY
Preliminary results of a single arm Phase II trial of intraoperative intravesical Mitomycin C during Nephroureterectomy for Urothelial Carcinoma.
IMPACT OF 18F-FLUCICLOVINE PET/CT ON PLANS FOR ADT IN PATIENTS WITH BIOCHEMICAL RECURRENCE OF PROSTATE CANCER; DATA ANALYSIS FROM TWO PROSPECTIVE CLINICAL TRIALS
PHASE 1/2A TWO YEAR RECURRENCE FREE SURVIVAL AND MARKER LESION RESPONSE RATE FOR PROLIPOSOMAL PACLITAXEL (TSD-001) IN INTERMEDIATE RISK NMIBC
SWOG S1931 (PROBE): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer [NCT04510597]